サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1259802

ユーイング肉腫治療薬市場のシェア・規模・動向・産業分析・予測 (2023年～2032年)： 薬剤クラス (ビンクリスチン・シクロホスファミド・ドキソルビシン・エトポシド・インフォポシド・ダクチノマイシン)・治療法・用途・地域別

Ewing Sarcoma Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Infoposide, Dactinomycin); By Treatment; By Application; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
ユーイング肉腫治療薬市場のシェア・規模・動向・産業分析・予測 (2023年～2032年)： 薬剤クラス (ビンクリスチン・シクロホスファミド・ドキソルビシン・エトポシド・インフォポシド・ダクチノマイシン)・治療法・用途・地域別
出版日: 2023年03月01日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のユーイング肉腫治療薬の市場規模は、2032年には4億2,442万米ドルの規模に成長すると予測されています。

当レポートでは、世界のユーイング肉腫治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のユーイング肉腫治療薬市場の洞察

  • 用途の概要
  • 市場力学
    • 推進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 用途の動向
  • バリューチェーン分析
  • COVID-19：影響分析

第5章 世界のユーイング肉腫治療薬市場：薬剤クラス別

  • 主な調査結果
  • ビンクリスチン
  • シクロホスファミド
  • ドキソルビシン
  • エトポシド
  • インフォポシド
  • ダクチノマイシン

第6章 世界のユーイング肉腫治療薬市場：治療法別

  • 主な調査結果
  • 化学療法
  • 放射線
  • 手術

第7章 世界のユーイング肉腫治療薬市場：用途別

  • 主な調査結果
  • 骨腫瘍
  • 軟部組織腫瘍
  • アスキン腫瘍

第8章 世界のユーイング肉腫治療薬市場：地域別

  • 主な調査結果
  • 北米
  • 欧州
  • アジア太平洋
  • 中東およびアフリカ
  • ラテンアメリカ

第9章 競合情勢

  • 拡張・買収の分析
  • 提携/協力/合意/展示会

第10章 企業プロファイル

  • Abbott
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bausch
  • Bayer
  • Bristol Squibb
  • Eli Lilly
  • Merck
  • AbbVie Inc
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Sanofi
図表

List of Tables

  • Table 1 Global Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 2 Global Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 3 Global Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 4 Ewing Sarcoma Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 6 North America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 7 North America: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 8 U.S.: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 9 U.S.: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 10 U.S.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 11 Canada: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 12 Canada: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 13 Canada: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 14 Europe: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 15 Europe: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 16 Europe: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 17 UK: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 18 UK: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 19 UK: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 20 France: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 21 France: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 22 France: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 23 Germany: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 24 Germany: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 25 Germany: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 26 Italy: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 27 Italy: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 28 Italy: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 29 Spain: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 30 Spain: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 31 Spain: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 32 Netherlands: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 33 Netherlands: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 34 Netherlands: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 35 Russia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 36 Russia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 37 Russia: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 41 China: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 42 China: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 43 China: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 44 India: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 45 India: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 46 India: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 47 Malaysia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 48 Malaysia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 49 Malaysia: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 50 Japan: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 51 Japan: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 52 Japan: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 53 Indonesia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 54 Indonesia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 55 Indonesia: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 56 South Korea: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 57 South Korea: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 58 South Korea: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 65 UAE: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 66 UAE: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 67 UAE: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 68 Israel: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 69 Israel: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 70 Israel: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 71 South Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 72 South Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 73 South Africa: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 74 Latin America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 75 Latin America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 76 Latin America: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 77 Mexico: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 78 Mexico: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 79 Mexico: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 80 Brazil: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 81 Brazil: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 82 Brazil: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • Table 83 Argentina: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • Table 84 Argentina: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • Table 85 Argentina: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Ewing Sarcoma Therapeutics Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Ewing Sarcoma Therapeutics Market, by Treatment, 2021 & 2030 (USD Million)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Ewing Sarcoma Therapeutics Market, by Drug Class, 2021 & 2030 (USD Million)
  • Figure 10. Market by Application
  • Figure 11. Global Ewing Sarcoma Therapeutics Market, by Application, 2021 & 2030 (USD Million)
  • Figure 12. Ewing Sarcoma Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Ewing Sarcoma Therapeutics Market
目次
Product Code: PM3053

The global Ewing sarcoma therapeutics market size is expected to reach USD 424.42 million by 2032, according to a new study by Polaris Market Research. The report "Ewing Syndrome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Infoposide, Dactinomycin); By Treatment; By Application; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Global growth in illness knowledge and incidence, as well as efforts made by government organizations, are driving the Ewing sarcoma market. Ewing sarcoma affects 2.9 children per 100,000 each year, according to the National Organization for Rare Diseases. Every year, around 200-250 children and adolescents in the United States are diagnosed with Ewing family tumors, with two-thirds expected to survive a long period.

Other factors driving the Ewing sarcoma therapy market include increased R&D and technology breakthroughs in diagnostics supporting market expansion. In May 2021, CancerVAX, Inc. launched research programmed to create the company's first Immunotherapy cancer treatment, which would mostly target Ewing sarcoma. Wings for Ewing Sarcoma, a non-profit 501(c)(3) group, is also working to discover a cure for the illness. They seek to empower children and young adults who are presently fighting until a treatment is discovered.

Drugs that target the IGF-1R, a protein present on the certain type of cancer cells that stimulates them to proliferate, are in clinical studies. Early research suggests that medications like these, such as ganitumab, can reduce some Ewing tumors while slowing the growth of others. In most situations, this improvement has only been transitory. These treatments may perform best when combination with additional medications, which are currently being investigated.

Ewing sarcoma, the second most frequent kind of bone tumor in children, is caused by an aberrant protein known as EWS/FLI. In January 2018, according to researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a new class of cancer medications known as CDK inhibitors may be able to disarm EWS/FLI.

Ewing Syndrome Therapeutics Market Report Highlights:

Chemotherapy treatment accelerated the overall growth of the market as chemotherapy employs a stronger treatment pathway for treatment of ewing sarcoma.

Bone tumor accounted for high CAGR as it has most frequent types of ewing tumors due to different types of cells forming tumors as compared to osteosarcoma cells.

North America has the biggest market share due to the rising frequency of Ewing sarcoma and the ease with which medicines are available.

The global players Abbott, AbbVie, Amgen Inc, AstraZeneca, Bausch, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, AbbVie Inc, GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi.

Polaris Market Research has segmented the Ewing sarcoma therapeutics market report based on drug class, treatment, application, and region:

Ewing Sarcoma Therapeutics, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

Vincristine,

Cyclophosphamide

Doxorubicin

Etoposide

Infoposide

Dactinomycin

Ewing Sarcoma Therapeutics, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

Chemotherapy

Radiation

Surgery

Ewing Sarcoma Therapeutics, Application Outlook (Revenue - USD Million, 2019 - 2032)

Bone Tumor

Soft Tissue Tumor

Askin Tumor

Ewing Sarcoma Therapeutics, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Ewing Sarcoma Therapeutics Market Insights

  • 4.1. Ewing Sarcoma Therapeutics Market - Application Snapshot
  • 4.2. Ewing Sarcoma Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased frequency of bone-related illnesses
      • 4.2.1.2. Substantial investment by private businesses
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost for treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Ewing Sarcoma Therapeutics Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Ewing Sarcoma Therapeutics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
  • 5.3. Vincristine
    • 5.3.1. Global Ewing Sarcoma Therapeutics Market, by Vincristine, by Region, 2019-2032 (USD Million)
  • 5.4. Cyclophosphamide
    • 5.4.1. Global Ewing Sarcoma Therapeutics Market, by Cyclophosphamide, by Region, 2019-2032 (USD Million)
  • 5.5. Doxorubicin
    • 5.5.1. Global Ewing Sarcoma Therapeutics Market, by Doxorubicin, by Region, 2019-2032 (USD Million)
  • 5.6. Etoposide
    • 5.6.1. Global Ewing Sarcoma Therapeutics Market, by Etoposide, by Region, 2019-2032 (USD Million)
  • 5.7. Infoposide
    • 5.7.1. Global Ewing Sarcoma Therapeutics Market, by Infoposide, by Region, 2019-2032 (USD Million)
  • 5.8. Dactinomycin
    • 5.8.1. Global Ewing Sarcoma Therapeutics Market, by Dactinomycin, by Region, 2019-2032 (USD Million)

6. Global Ewing Sarcoma Therapeutics Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • 6.3. Chemotherapy
    • 6.3.1. Global Ewing Sarcoma Therapeutics Market, by Chemotherapy, by Region, 2019-2032 (USD Million)
  • 6.4. Radiation
    • 6.4.1. Global Ewing Sarcoma Therapeutics Market, by Radiation, by Region, 2019-2032 (USD Million)
  • 6.5. Surgery
    • 6.5.1. Global Ewing Sarcoma Therapeutics Market, by Surgery, by Region, 2019-2032 (USD Million)

7. Global Ewing Sarcoma Therapeutics Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
  • 7.3. Bone Tumour
    • 7.3.1. Global Ewing Sarcoma Therapeutics Market, by Bone Tumour, By Region, 2019-2032 (USD Million)
  • 7.4. Soft Tissue Tumour
    • 7.4.1. Global Ewing Sarcoma Therapeutics Market, by Soft Tissue Tumour, By Region, 2019-2032 (USD Million)
  • 7.5. Askin Tumour
    • 7.5.1. Global Ewing Sarcoma Therapeutics Market, by Askin Tumour, By Region, 2019-2032 (USD Million)

8. Global Ewing Sarcoma Therapeutics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Ewing Sarcoma Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Ewing Sarcoma Therapeutics Market - North America
    • 8.3.1. North America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.2. North America: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
    • 8.3.3. North America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.3.4. Ewing Sarcoma Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.3.5. Ewing Sarcoma Therapeutics Market - Canada
      • 8.3.5.1. Canada: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • 8.4. Ewing Sarcoma Therapeutics Market - Europe
    • 8.4.1. Europe: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
    • 8.4.3. Europe: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.4. Ewing Sarcoma Therapeutics Market - UK
      • 8.4.4.1. UK: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.5. Ewing Sarcoma Therapeutics Market - France
      • 8.4.5.1. France: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.5.3. France: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.6. Ewing Sarcoma Therapeutics Market - Germany
      • 8.4.6.1. Germany: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.7. Ewing Sarcoma Therapeutics Market - Italy
      • 8.4.7.1. Italy: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.8. Ewing Sarcoma Therapeutics Market - Spain
      • 8.4.8.1. Spain: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.9. Ewing Sarcoma Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.10. Ewing Sarcoma Therapeutics Market - Russia
      • 8.4.10.1. Russia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • 8.5. Ewing Sarcoma Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.4. Ewing Sarcoma Therapeutics Market - China
      • 8.5.4.1. China: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.4.3. China: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.5. Ewing Sarcoma Therapeutics Market - India
      • 8.5.5.1. India: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.5.3. India: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.6. Ewing Sarcoma Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.7. Ewing Sarcoma Therapeutics Market - Japan
      • 8.5.7.1. Japan: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.8. Ewing Sarcoma Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.9. Ewing Sarcoma Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • 8.6. Ewing Sarcoma Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.4. Ewing Sarcoma Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.5. Ewing Sarcoma Therapeutics Market - UAE
      • 8.6.5.1. UAE: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.6. Ewing Sarcoma Therapeutics Market - Israel
      • 8.6.6.1. Israel: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.7. Ewing Sarcoma Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
  • 8.7. Ewing Sarcoma Therapeutics Market - Latin America
    • 8.7.1. Latin America: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.4. Ewing Sarcoma Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.5. Ewing Sarcoma Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.6. Ewing Sarcoma Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Ewing Sarcoma Therapeutics Market, by Drug Class, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Ewing Sarcoma Therapeutics Market, by Application, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Ewing Sarcoma Therapeutics Market, by Treatment, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AbbVie
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Amgen
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. AstraZeneca
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bausch
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Bayer
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bristol Squibb
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Eli Lilly
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. AbbVie Inc
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. GlaxoSmithKline
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Johnson & Johnson
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Novartis
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sanofi
    • 10.14.1. Company Overview
    • 10.14.2. Financial PerTreatmentance
    • 10.14.3. Treatment Benchmarking
    • 10.14.4. Recent Development